Rhythm Pharmaceuticals stock price target raised to $109 from $95 at BofA

BofA Securities has raised its price target on Rhythm Pharmaceuticals (NASDAQ:RYTM) to $109 from $95, maintaining a Buy rating, following positive Phase 2 data for its next-generation oral MC4R agonist, bivamelagon (biva). The data suggests biva offers efficacy consistent with setmelanotide but with potentially improved tolerability, particularly lower hyperpigmentation, which could significantly expand market uptake in rare genetic obesity disorders. RYTM has seen a 36.86% gain in the past week, and BofA projects peak risk-adjusted sales of $1.7 billion for biva in heterozygous obesity, aligning with other analysts like Oppenheimer, Morgan Stanley, and Goldman Sachs who also hold positive outlooks, further bolstered by a recent $175 million upsized public offering.

Analysis

Rhythm Pharmaceuticals (RYTM) has garnered significant positive attention following a price target increase from BofA Securities to $109.00 from $95.00, driven by promising Phase 2 topline data for its oral MC4R agonist, bivamelagon. The stock has responded with a 36.86% gain in the past week, trading near its 52-week high. The primary driver of this optimism is bivamelagon's potential to offer efficacy comparable to the company's existing drug, setmelanotide, but with a superior safety and tolerability profile, specifically a lower incidence of hyperpigmentation. According to an expert endocrinologist cited by BofA, this improved tolerability could lead most heterozygous obesity patients to prefer bivamelagon, thereby expanding the addressable market. BofA is now modeling $1.7 billion in peak risk-adjusted sales for the drug, assuming a 60% probability of success and a 2029 launch. This bullish sentiment is echoed across Wall Street, with Oppenheimer ($110), Citizens JMP ($130), and Goldman Sachs ($97) all issuing positive ratings and targets. The company has also strengthened its financial position by pricing an upsized public offering to raise approximately $175 million, funding further development. Despite impressive gross profit margins of 89.62%, the company is not yet profitable, a key factor to consider amidst the pipeline-driven optimism.

Key Decisions for Investors

• The strong consensus among analysts and positive Phase 2 data for bivamelagon support a continued bullish stance, as the drug's improved tolerability profile could unlock a significantly larger market than setmelanotide.
• Investors should monitor upcoming longer-term efficacy and safety data for bivamelagon, as these will be critical catalysts for validating the peak sales projections and sustaining the stock's recent momentum.
• While the recent $175 million capital raise de-risks the company's development runway, investors should be mindful of the stock's valuation near its 52-week high and the company's current lack of overall profitability.